Screener
Rapport Therapeutics, Inc. RAPP Income Statement
| Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | ||
|---|---|---|---|---|---|---|
| $0— | $20M— | —— | —— | $0— | ||
| $51.41M+127% | $32.72M+67.2% | $30.26M+75.9% | $22.28M+43.3% | $22.68M+44.6% | ||
| $9.39M+37.8% | $11.5M+52.6% | —— | —— | $6.82M— | ||
| $60.81M+106% | $44.22M+63.1% | $38.51M+63.7% | $29.99M+38.6% | $29.5M+41.8% | ||
| -$60.81M-106% | -$24.22M+10.7% | -$38.51M-63.7% | -$29.99M-38.6% | -$29.5M-41.8% | ||
| $4.19M+51.6% | $4.36M+43.1% | $4.75M+34.0% | $3.06M-25.4% | $2.76M+3.2% | ||
| -$56.62M-112% | -$19.86M+17.5% | -$33.76M-69.0% | -$26.93M-53.5% | -$26.73M-47.5% | ||
| -$1.19-58.7% | -$0.42+38.2% | -$0.71-492% | -$0.71-42.0% | -$0.75+55.9% | ||
| -$60.59M-107% | -$23.99M+10.7% | -$38.24M-64.4% | -$29.73M-38.8% | -$29.24M-42.0% | ||
| -$60.81M-106% | -$24.22M+10.7% | -$38.51M-63.7% | -$29.99M-38.6% | -$29.5M-41.8% |
FAQ
- What is Rapport Therapeutics, Inc.'s revenue?
- Rapport Therapeutics, Inc. (RAPP) generated $20.0M in revenue over the trailing twelve months.
- Is Rapport Therapeutics, Inc. profitable?
- Rapport Therapeutics, Inc. is not currently profitable: it reported a net loss of $137.2M over the trailing twelve months, a -685.8% net margin.
- What is Rapport Therapeutics, Inc.'s earnings per share?
- Rapport Therapeutics, Inc.'s diluted EPS over the trailing twelve months is $-3.03.
- Where does Rapport Therapeutics, Inc.'s income statement data come from?
- Every line is extracted from Rapport Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
